Revolution Medicines, Inc. filings document a late-stage clinical oncology company focused on RAS-addicted cancers and RAS(ON) inhibitors. Its Form 8-K reports include financial results, clinical-program updates for daraxonrasib and other pipeline candidates, regulatory-related disclosures and material events tied to corporate progress.
The company’s SEC record also covers proxy governance, annual meeting matters, executive compensation, registered securities and capital-structure changes. Disclosures identify Nasdaq-listed common stock and warrants, and material-agreement filings describe convertible senior notes due 2033, related indenture terms and other financing arrangements used to support research and development, administrative expenses and potential commercialization activities.
Revolution Medicines (RVMD) announced an FDA milestone. On October 16, 2025, the U.S. Food and Drug Administration granted the company a non‑transferrable voucher for daraxonrasib, its RAS(ON) multi‑selective inhibitor, under the Commissioner’s National Priority Voucher pilot program.
This update signals regulatory recognition tied to daraxonrasib’s program status. The voucher is non‑transferrable and is associated specifically with the FDA’s pilot initiative. No financial terms or commercial arrangements were disclosed in this notice.
Revolution Medicines (RVMD) reported an insider transaction by an officer on 10/13/2025. The reporting person exercised 25,000 stock options at an exercise price of $4.73 per share, then sold 25,000 shares of common stock at a weighted average price of $48.5416. The trades were made under a Rule 10b5-1 trading plan adopted on February 28, 2025.
Following these transactions, the reporting person beneficially owned 284,047 shares, which includes 84,000 restricted stock units, held directly. The filing also shows 5,055 derivative securities (stock options) remaining beneficially owned. The officer’s title is President, Research and Development.
Jeff Cislini, General Counsel of Revolution Medicines, Inc. (RVMD), reported an insider sale. On 09/24/2025 he disposed of 1,799 shares of common stock at a price of $44.26 per share under a previously adopted 10b5-1 trading plan. After the sale he beneficially owned 50,425 shares in total, which the filing specifies includes 43,910 restricted stock units. The Form 4 was signed on behalf of Mr. Cislini by an attorney-in-fact on 09/26/2025.
Revolution Medicines insider filing details a small, routine proposed sale of company stock. The notice reports that Jeffrey Todd Cislini plans to sell 1,799 common shares through Morgan Stanley Smith Barney on 09/24/2025, with an aggregate market value of $79,524.80 based on the filing. The shares were acquired as restricted stock units on 09/15/2025 and payment or settlement is recorded on that same acquisition date. The filer also disclosed a prior sale of 1,869 shares on 09/16/2025 for gross proceeds of $85,646.74. The filing includes the standard representation that the seller is not aware of undisclosed material information.
Wei Lin, Chief Medical Officer of Revolution Medicines, Inc. (ticker shown in filing as RVMD), reported a sale of 2,160 shares of Common Stock on 09/16/2025 at a price of $45.8249 per share. The filing states the sale was made under a Rule 10b5-1 instruction adopted on December 23, 2024 to satisfy the reporting person’s tax withholding obligation upon the vesting of restricted stock units (RSUs) after March 15, 2025. After the transaction, Wei Lin beneficially owned 88,339 shares, which the filing notes includes 58,850 restricted stock units. The form was signed by an attorney-in-fact on behalf of Wei Lin on 09/18/2025.
Revolution Medicines insider sale to cover RSU taxes — The company's President of Research and Development, Stephen Michael Kelsey, reported a sale of 5,367 shares of common stock at $45.8249 per share executed under a Rule 10b5-1 plan to satisfy tax withholding on restricted stock unit vesting. After the transaction the filing reports beneficial ownership of 284,047 shares, which includes 84,000 RSUs. The sale is described as pursuant to a pre-existing 10b5-1 instruction adopted in May 2023.
Margaret A. Horn, Chief Operating Officer and Director of Revolution Medicines, reported a sale of 4,775 shares of the issuer's common stock on 09/16/2025 at a reported price of $45.8249 per share. After the transaction she beneficially owns 145,900 shares, which the filing states includes 70,500 restricted stock units (RSUs). The sale was executed under a Rule 10b5-1 instruction letter adopted May 31, 2023, to satisfy the reporting person's tax withholding obligations upon RSU vesting after July 15, 2023. The Form 4 was signed by an attorney-in-fact on behalf of Ms. Horn on 09/18/2025.
Insider sale to cover taxes: This Form 4 shows Jeff Cislini, General Counsel of Revolution Medicines, executed a sale of 1,869 shares of common stock on 09/16/2025 at $45.8249 per share under a Rule 10b5-1 plan adopted May 31, 2023 to satisfy tax withholding for vested restricted stock units (RSUs). After the transaction he beneficially owns 52,224 shares, which includes 43,910 RSUs. The filing was signed by an attorney-in-fact on 09/18/2025. The disclosure is a routine insider tax-withholding sale rather than a discretionary trade.
Revolution Medicines insider sale to cover tax withholding following RSU vesting. Chief Financial Officer Jack Anders reported a sale of 2,320 shares of Revolution Medicines common stock on 09/16/2025 at an average price of $45.8249 per share, executed under a pre-existing Rule 10b5-1 instruction adopted May 31, 2023 to satisfy tax withholding obligations tied to RSU vesting after July 15, 2023. After the transaction Mr. Anders beneficially owned 110,994 shares, which the filing notes includes 48,275 restricted stock units. The Form 4 is signed and dated 09/18/2025.
Revolution Medicines, Inc. (RVMD) Form 144 discloses a proposed sale of 2,131 shares of common stock through ETRADE with an aggregate market value of $99,198.05, with an approximate sale date of 09/15/2025 on NASDAQ. The securities originated from restricted stock unit grants received from the issuer on 05/01/2023 (1,253 shares), 03/01/2024 (412 shares) and 03/01/2025 (466 shares), each noted as payment for services rendered. The filing also reports a prior sale by the same person of 2,173 shares on 06/16/2025 generating $86,550.59. The filer certifies no undisclosed material adverse information is known.